Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product (Organ(s) based Models and Disease(s) based Models), Application Area (Cancer Research, Drug Discovery and Toxicity Testing, Stem Cell Research and Tissue Engineering and Regenerative Medicine), Purpose (Research and Therapeutic Production), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Slides
    143

  • View Count
    165

Example Insights

Organ-on-Chip-Market-Context-thumb Organ-on-Chip-Market-List-thumb Organ-on-Chip-Market-Market-Landscape-thumb
Organ-on-Chip-Market-Developers-thumb Organ-on-Chip-Market-Patent-Analysis-thumb Organ-on-Chip-Market-Partnerships-and-Collaborations-thumb
Organ-on-Chip-Market-Grant-Analysis-thumb Organ-on-Chip-Market-Funding-and-Investment-thumb Organ-on-Chip-Market-Forecasted-Opportunity-thumb

Overview

It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry.  The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans. Moreover, these studies are quite expensive, time-consuming and are associated with several ethical concerns. In order to reform the drug approval process and use non-animal testing models for preclinical evaluations, the US democrats and republicans introduced the FDA Modernization Act in 2021. The U.S. Environmental Protection Agency (EPA) has also declared the termination of the funds granted for the studies on mammals by 2035. As a result, several stakeholders have opted to modernize their conventional testing methods in order to cope up with the increasing limitations associated with animal models. One such innovative technology, 'organ on a chip’ has the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. The use of such novel testing models in drug discovery and toxicity testing has been steadily increasing. Up till now, several pharmaceutical manufacturers and research institutions have embraced the use of these in vivo like in vitro models; however, a remarkable rise in the adoption rate of these models has been observed since the FDA changed its laws towards putting an end on the animal testing models. The novel organ on a chip models have various advantages over the traditional animal-based models, including fine control over microenvironment, lower cost, lesser time, easy to use and portable. Given the inherent benefits of organ on a chip technology, a number of players have launched their proprietary products in order to expedite preclinical studies of novel drug interventions across a wide array of disease indications. There are several organ on a chip models, including lung-on-chip, liver-on-chip, heart-on-chip, brain-on-chip and multiple organ models, which are being offered by various players. Apart from offering efficient user-friendly organ-on-chip models, some developers also offer customization of these models as per the client requests. It is worth mentioning that various developers have made significant efforts in developing organ on chip technologies, paving the way for new innovations, primarily integrating artificial intelligence driven technology for early detection of pharmaceuticals and toxicity risks, along with detection of unknown mutations. Driven by promising benefits over animal testing, increasing R&D activity and financial support from investors, the organ on a chip market is anticipated to grow at a commendable pace in the mid to long term.

Scope of the Report

The “Organ on a Chip Market, 2022-2035: Focus on Products and Technologies - Distribution by Type of Product (Organ(s) based Models and Disease(s) based Models), Application Area (Cancer Research, Drug Discovery and Toxicity Testing, Stem Cell Research and Tissue Engineering and Regenerative Medicine), Purpose (Research and Therapeutic Production), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of organ-on-chip products and technologies, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A general introduction of organ on a chip, including history and development, classification, advantages and limitations and applications and future perspectives of organ on a chip.
  • A detailed assessment of the current market landscape of organ-on-chips based on a number of relevant parameters, such as type of offering(s) (chip, plate / system, and technology), type of model (organ(s) based and disease(s) based), status of development (commercialized, developed, and under development), type of technology / platform, number of chips in a plate, material used for construction of chip / plate (polymer, glass and silicon), type of polymer (polydimethylsiloxane, cyclic olefin polymer, cyclic olefin copolymer, elastomer, polycarbonate, polypropylene, polystyrene, polyester, tygon, and styrene TEP), compatible tissue / organ, and application area (cancer research, drug discovery and toxicity testing, stem cell research, and tissue engineering and regenerative medicine). In addition, the chapter provides details on the companies engaged in the development of organ-on-chip products and technologies, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of the key players developing organ-on-chips (which are presently commercialized), which are headquartered in North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), organ-on-chip product portfolio, recent developments, and an informed future outlook.
  • An in-depth analysis of various patents that have been filed / granted for organ on a chip, till 2022, based on various relevant parameters, such as type of patent, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes an insightful patent valuation analysis.
  • A detailed brand positioning analysis of the key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products and technologies offered, product diversity, and number of patents published.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to organ on a chip, between 2017 and 2022, based on parameters, such as year of award, support period, amount awarded, funding institute center, grant type, emerging focus area, type of recipient organization, key regions, and leading recipient organizations.
  • An analysis of the partnerships that have been established since 2017, covering various types of partnerships, such as research and development agreements, clinical trial agreements, product development and commercialization agreements, technology integration agreements, and product development and manufacturing agreements of the companies focused on developing organ-on-chip products and technologies.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small companies (with less than 50 employees) and mid-sized companies (with 51-200 employees) that are focused on developing organ on a chip products and technologies.
  • A case study on scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of organ-on-chip market. Based on multiple parameters, such as overall 3D cell culture market, and share of organ on a chip, we have provided informed estimates of the evolution of the market for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of type of product (organ(s) based models and disease(s) based models), application area (cancer research, drug discovery and toxicity testing, stem cell research and tissue engineering and regenerative medicine), purpose (research and therapeutic production), key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of discussions held with the following individuals (in alphabetical order of company / organization names)

  • Pierre Gaudriault, (Chief Business Development Officer, Cherry Biotech)
  • Matt Dong-Heon Ha (Chief Executive Officer, EDmicBio)
  • Michael Shuler (President, Hesperos)
  • Jelena Vukasinovic (Chief Executive Officer, Lena Biosciences)
  • Maurizio Aiello (Chief Executive Officer, react4life)
  • Michele Zagnoni (Chief Executive Officer, ScreenIn3D)

Key Questions Answered

  • Who are the leading players engaged in the development of organ-on-chip products and technologies?
  • What are the different application areas where organ on a chip can be used?
  • Primarily in which geographical regions, are the organ on a chip developers located?
  • How has the intellectual property landscape of organ on a chip, evolved over the years?
  • Which partnership models are commonly adopted by stakeholders in the organ on a chip domain?
  • What are the investment trends and who are the key investors actively engaged in the research and development of organ on a chip systems?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Overview
1.2. Scope of the Report
1.3. Research Methodology
1.4. Key Questions Answered 
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Background of Organ-on-Chip
3.3. Classification of Organ-on-Chip
3.3.1. Single Organ Chip
3.3.2. Disease / Therapeutic Indication Specific Chip
3.3.3. Multi Organ Chip
3.4. Advantages and Limitations of Organ-on-Chip
3.5. Applications of Organ-on-Chip
3.6. Future Perspectives

4. ORGAN-ON-CHIP: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Organ-on-Chip: List of Products
4.2.1. Analysis by Type of Offering(s)
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Type of Technology / Platform
4.2.4. Analysis by Number of Chips in a Plate
4.2.5. Analysis by Material Used for Construction of Chip / Plate
4.2.6. Analysis by Type of Polymer
4.2.7. Analysis by Compatible Tissue / Organ
4.2.8. Analysis by Application Area(s)

4.3. Organ-on-Chip: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Organ-on-Chip Products

5. ORGAN-ON-CHIP DEVELOPERS: COMPANY PROFILES
5.1. Chapter Overview
5.2. BEOnChip
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Developments and Future Outlook

5.3. Dynamic42
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Developments and Future Outlook

5.4. Emulate
5.4.1. Company Overview
5.4.2. Product Portfolio
5.4.3. Recent Developments and Future Outlook

5.5. Mimetas
5.5.1. Company Overview
5.5.2. Product Portfolio
5.5.3. Recent Developments and Future Outlook

5.6. SynVivo
5.6.1. Company Overview
5.6.2. Product Portfolio
5.6.3. Recent Developments and Future Outlook

5.7 TissUse
5.7.1. Company Overview
5.7.2. Product Portfolio
5.7.3. Recent Developments and Future Outlook

5.8 uFluidix
5.8.1. Company Overview
5.8.2. Product Portfolio
5.8.3. Recent Developments and Future Outlook

6. PATENT ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Organ-on-Chip: Patent Analysis
6.3.1. Analysis by Type of Patent
6.3.2. Analysis by Publication Year
6.3.3. Analysis by Annual Granted Patents
6.3.4. Analysis by Annual Patent Application
6.3.5. Analysis by Annual Granted Patents and Patent Application
6.3.6. Analysis by Location of Headquarters
6.3.7. Analysis by Type of Applicant
6.3.8. Analysis by Patent Age
6.3.9. Analysis by Geographical Region
6.3.10. Analysis by CPC Symbols
6.3.11. Leading Industry Players: Analysis by Number of Patents
6.3.12. Leading Non-Industry Players: Analysis by Number of Patents
6.3.13 Leading Inventors: Analysis by Number of Patents

6.4. Patent Benchmarking Analysis
6.4.1.   Analysis by Patent Characteristics

6.5. Analysis by Patent Valuation

7. BRAND POSITIONING MATRIX
7.1. Chapter Overview
7.2 Methodology
7.3. Key Parameters
7.4. Companies Providing Organ-on-Chip
7.4.1. Brand Positioning Matrix: BiomimX
7.4.2. Brand Positioning Matrix: Emulate
7.4.3. Brand Positioning Matrix: NETRI
7.4.4.   Brand Positioning Matrix: SynVivo
7.4.5. Brand Positioning Matrix: TissUSe
7.4.6. Brand Positioning Matrix: uFluidix

8. ACADEMIC GRANTS ANALYSIS
8.1 Chapter Overview
8.2. Scope and Methodology
8.3. Organ-on-Chip: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Grant Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period 
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Administering Institute Center and Amount Awarded (USD Million)
8.3.7. Analysis by Type of Grant Application
8.3.8. Analysis by Purpose of Grant 
8.3.9. Analysis by Activity Code
8.3.10. Word Cloud Analysis: Emerging Focus Area
8.3.11. Analysis by Study Section Involved
8.3.12. Popular NIH Departments:  Analysis by Number of Grants
8.3.13. Analysis by Type of Recipient Organization
8.3.14. Analysis by Support Period and Amount Awarded
8.3.15. Popular Recipient Organizations: Analysis by Number of Grants
8.3.16. Popular Recipient Organizations: Analysis by Amount Awarded
8.3.17. Popular Recipient Organizations: Analysis by Geographical Location

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Organ-on-Chip: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Analysis by Geographical Region
9.3.4.1 Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Organ-on-Chip: List of Funding and Investments
10.2.1. Analysis by Annual Instances
10.2.2. Analysis by Amount Invested per Year
10.2.3. Analysis by Type of Funding 
10.2.4. Analysis by Type of Funding and Year of Establishment
10.2.5. Analysis by Type of Funding and Amount Invested
10.2.6. Analysis of Amount Invested by Geographical Region
10.2.7. Analysis by Purpose of Funding
10.2.8. Analysis by Associated Organ / System
10.2.9. Analysis by Therapeutic Area
10.2.10. Most Prominent Investors: Analysis by Number of Instances
10.2.11. Most Active Players: Analysis by Number of Funding Instances
10.2.12. Most Active Players: Analysis by Amount Raised
10.2.13. Summary of Investments

11. CASE STUDY: SCAFFOLD-FREE 3D CELL CULTURE SYSTEMS
11.1. Chapter Overview
11.2. Scaffold-free Products: Market Landscape
11.2.1. Analysis by Status of Development
11.2.2. Analysis by Type of Product
11.2.3. Analysis by Source of 3D Cultured Cells
11.2.4. Analysis by Method Used for Fabrication
11.2.5. Analysis by Material Used for Fabrication
11.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
11.2.7. Analysis by Type of Product and Method Used for Fabrication

11.3. Scaffold Free Products: Developer Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3.  Analysis by Location of Headquarters

11.4.  Leading Developers: Analysis by Number of Scaffold Free Products
11.5.  Tree Map Representation: Analysis by Type of Product and Company Size

12. ORGAN-ON-CHIP: MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1.   Chapter Overview
12.2.   Forecast Methodology and Key Assumptions
12.3.   Global Organ-on-Chip Market, 2022-2035
12.3.1. Global Organ-on-Chip Market, 2022-2035: Distribution by Type of Product
12.3.1.1. Organ-on-Chip Market for Organ(s) based Models, 2022-2035
12.3.1.2. Organ-on-Chip Market for Disease(s) based Models, 2022-2035

12.3.2. Global Organ-on-Chip Market, 2022-2035: Distribution by Application Area
12.3.2.1. Organ-on-Chip Market for Cancer Research, 2022-2035
12.3.2.2. Organ-on-Chip Market for Drug Discovery and Toxicity Testing, 2022-2035
12.3.2.3. Organ-on-Chip Market for Stem Cell Research, 2022-2035
12.3.2.4. Organ-on-Chip Market for Tissue Engineering and Regenerative Medicine, 2022-2035

12.3.3. Global Organ-on-Chip Market, 2022-2035: Distribution by Purpose
12.3.3.1. Organ-on-Chip Market for Research Purposes, 2022-2035
12.3.3.2. Organ-on-Chip Market for Therapy Development, 2022-2035

12.3.4. Global Organ-on-Chip Market, 2022-2035: Distribution by Key Geographical Regions
12.3.4.1. Organ-on-Chip Market in North America, 2022-2035
12.3.4.2. Organ-on-Chip Market in Europe, 2022-2035
12.3.4.3. Organ-on-Chip Market in Asia-Pacific, 2022-2035
12.3.4.4. Organ-on-Chip Market in Rest of the World, 2022-2035

13. CONCLUSION

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Cherry Biotech
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Pierre Gaudriault, Chief Business Development Officer

14.3. EDmicBio
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Matt Dong-Heon Ha, Chief Executive Officer

14.4. Hesperos
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Michael Shuler, President

14.5. Lena Biosciences
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Jelena Vukasinovic, Chief Executive Officer

14.6. react4life
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Maurizio Aiello, Chief Executive Officer 

14.7. Screenin3D
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Michele Zagnoni, Chief Executive Officer

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1. Executive Summary: Overall Market Landscape of Organ-on-Chip Products / Technologies
Figure 2.2. Executive Summary: Patent Analysis
Figure 2.3. Executive Summary: Brand Positioning
Figure 2.4. Executive Summary: Grant Analysis
Figure 2.5. Executive Summary: Partnerships and Collaborations
Figure 2.6. Executive Summary: Funding and Investment Analysis
Figure 2.7. Executive Summary: Organ-on-Chip Market Sizing and Opportunity Analysis
Figure 3.1. Background of Organ-on-Chip
Figure 3.2. Types of Organ-on-Chip
Figure 3.3. Types of Single Organ-on-Chip
Figure 3.4. Advantages and Limitations of Organ-on-chip
Figure 3.5. Applications of Organ-on-Chip in Drug Discovery and Development
Figure 4.1. Organ-on-Chip: Distribution by Type of Offering(s)
Figure 4.2. Organ-on-Chip: Distribution by Type of Model
Figure 4.3. Organ-on-Chip: Distribution by Status of Development
Figure 4.4. Organ-on-Chip: Distribution by Type of Technology / Platform
Figure 4.5. Organ-on-Chip: Distribution by Number of Chips in a Plate
Figure 4.6. Organ-on-Chip: Distribution by Material Used for Construction of Chip / Plate
Figure 4.7. Organ-on-Chip: Distribution by Type of Polymer
Figure 4.8. Organ-on-Chip: Distribution by Compatible Tissue / Organ
Figure 4.9. Organ-on-Chip: Distribution by Application Area(s)
Figure 4.10. Organ-on-Chip: Distribution of Developers by Year of Establishment
Figure 4.11. Organ-on-Chip: Distribution of Developers by Company Size
Figure 4.12. Organ-on-Chip: Distribution of Developers by Location of Headquarters
Figure 4.13. Leading Developers: Distribution by Number of Organ-on-Chip Products
Figure 6.1. Patent Analysis: Distribution by Type of Patents
Figure 6.2. Patent Analysis: Cumulative Distribution by Publication Year
Figure 6.3. Patent Analysis: Distribution by Annual Granted Patents
Figure 6.4. Patent Analysis: Distribution by Annual Patent Applications
Figure 6.5. Patent Analysis: Distribution by Annual Granted Patents and Patent Applications
Figure 6.6. Patent Analysis: Distribution by Location of Headquarters
Figure 6.7. Patent Analysis: Distribution by Type of Applicant
Figure 6.8. Patent Analysis: Distribution by Patent Age
Figure 6.9. Patent Analysis: Distribution by Geographical Region
Figure 6.10. Patent Analysis: Distribution by CPC Symbols
Figure 6.11. Patent Analysis: Distribution by Leading Industry Players
Figure 6.12. Patent Analysis: Distribution by Leading Non-Industry Players
Figure 6.13. Patent Analysis: Distribution by Leading Inventors
Figure 6.14. Patent Analysis: Patent Valuation Analysis
Figure 7.1. Brand Positioning Matrix: BiomimX
Figure 7.2. Brand Positioning Matrix: Emulate
Figure 7.3. Brand Positioning Matrix: NETRI
Figure 7.4. Brand Positioning Matrix: SynVivo
Figure 7.5. Brand Positioning Matrix: TissUse
Figure 7.6. Brand Positioning Matrix: uFluidix
Figure 8.1. Academic Grants Analysis: Distribution by Cumulative Year-wise Trend
Figure 8.2. Academic Grants Analysis: Distribution by Grant Amount Awarded
Figure 8.3. Academic Grants Analysis: Distribution by Funding Institute Center
Figure 8.4. Academic Grants Analysis: Distribution by Support Period
Figure 8.5. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Figure 8.6. Academic Grants Analysis: Distribution by Type of Grant
Figure 8.7. Academic Grants Analysis: Distribution by Purpose of Grant
Figure 8.8. Academic Grants Analysis: Distribution by Activity Codes
Figure 8.9. Academic Grants Analysis: Emerging Focus Areas
Figure 8.10. Academic Grants Analysis: Distribution by Study Section
Figure 8.11. Academic Grants Analysis: Distribution by Most Popular NIH Department
Figure 8.12. Academic Grants Analysis: Distribution by Organization
Figure 8.13. Academic Grants Analysis: Distribution by Support Period and Amount Awarded
Figure 8.14. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Number of Grants
Figure 8.15. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Amount Awarded
Figure 8.16. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Geographical Location
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2022
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Figure 9.4. Partnerships and Collaborations: Distribution by Type of Collaborator
Figure 9.5. Partnerships and Collaborations: Distribution by Target Indication
Figure 9.6. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.7. Partnerships and Collaborations: Distribution by Associated Organ / Tissue
Figure 9.8. Most Active Players: Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
Figure 9.10. Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
Figure 9.11. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1. Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million), 2017-2022
Figure 10.2. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment, 2017-2022
Figure 10.3. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2017-2022
Figure 10.4. Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2017-2022
Figure 10.5. Funding and Investment Analysis: Distribution by Type of Funding
Figure 10.6. Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 10.7. Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 10.8. Funding and Investment Analysis: Distribution by Associated Organ / System
Figure 10.9. Funding and Investment Analysis: Distribution by Target Indication
Figure 10.10. Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 10.11. Funding and Investment Analysis: Distribution by Region
Figure 10.12. Most Active Players: Distribution by Number of Instances
Figure 10.13. Most Active Players: Distribution by Amount Raised (USD Million)
Figure 10.14. Key Investors: Distribution by Number of Funding Instances
Figure 10.15. Funding and Investment Summary, 2017-2022 (USD Million)
Figure 11.1. Scaffold-free 3D Cell Culture Systems: Distribution by Status of Development
Figure 11.2. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product
Figure 11.3. Scaffold-free 3D Cell Culture Systems: Distribution by Source of 3D Cultured Cells
Figure 11.4. Scaffold-free 3D Cell Culture Systems: Distribution by Method Used for Fabrication
Figure 11.5. Scaffold-free 3D Cell Culture Systems: Distribution by Material Used for Fabrication
Figure 11.6. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product and Source of 3D Cultured Cells
Figure 11.7. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product and Method Used for Fabrication
Figure 11.8. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Year of Establishment
Figure 11.9. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Company Size
Figure 11.10. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Location of Headquarters
Figure 11.11. Leading Developers: Analysis by Number of Scaffold Free Products
Figure 11.12. Tree Map Representation: Analysis by Type of Product and Company Size
Figure 12.1. Global Organ-on-Chip Market, 2022-2035 (USD Million)
Figure 12.2. Organ-on-Chip Market: Distribution by Type of Product, 2022 and 2035 (USD Million)
Figure 12.3. Organ-on-Chip Market for Multi-Organ(s) Based Models, 2022-2035 (USD Million)
Figure 12.4. Organ-on-Chip Market for Disease(s) Based Models, 2022-2035 (USD Million)
Figure 12.5. Organ-on-Chip Market: Distribution by Application Area, 2022 and 2035 (USD Million)
Figure 12.6. Organ-on-Chip Market for Cancer Research, 2022-2035 (USD Million)
Figure 12.7. Organ-on-Chip Market for Drug Discovery and Toxicity Testing, 2022-2035 (USD Million)
Figure 12.8. Organ-on-Chip Market for Stem Cell Research, 2022-2035 (USD Million)
Figure 12.9. Organ-on-Chip Market for Tissue Engineering and Regenerative Medicine, 2022-2035 (USD Million)
Figure 12.10. Organ-on-Chip Market: Distribution by Purpose, 2022 and 2035 (USD Million)
Figure 12.11. Organ-on-Chip Market for Research Purposes, 2022-2035 (USD Million)
Figure 12.12. Organ-on-Chip Market for Therapy Development, 2022-2035 (USD Million)
Figure 12.13. Organ-on-Chip Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Figure 12.14. Organ-on-Chip Market for North America, 2022-2035 (USD Million)
Figure 12.15. Organ-on-Chip Market for Europe, 2022-2035 (USD Million)
Figure 12.16. Organ-on-Chip Market for Asia-Pacific, 2022-2035 (USD Million)
Figure 12.17. Organ-on-Chip Market for Rest of the World, 2022-2035 (USD Million)
Figure 13.1. Concluding Remarks: Organ-on-Chip Market Landscape
Figure 13.2. Concluding Remarks: Patent Analysis
Figure 13.3. Concluding Remarks: Academic Grant Analysis
Figure 13.4. Concluding Remarks: Partnerships and Collaborations
Figure 13.5. Concluding Remarks: Funding and Investment Analysis
Figure 13.6. Concluding Remarks: Organ-on-Chip Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1. List of Organ-on-Chip Products and Technologies
Table 4.2. List of Organ-on-Chip Developers: Information on Year of Establishment, Company Size, Location of Headquarters, Geographical Region
Table 5.1. Organ-on-Chip Developers: List of Companies Profiled
Table 5.2. BEOnChip: Company Snapshot
Table 5.3. BEonChip: Key Characteristics of Organ-on-Chip Products
Table 5.4. SynVivo: Company Snapshot
Table 5.5. SynVivo: Key Characteristics of Organ-on-Chip Products
Table 5.6. Dynamic42: Company Snapshot
Table 5.7. Dynamic42: Key Characteristics of Organ-on-Chip Products
Table 5.8. Emulate: Company Snapshot
Table 5.9. Emulate: Key Characteristics of Organ-on-Chip Products
Table 5.10. Emulate: Recent Developments and Future Outlook
Table 5.11. Mimetas: Company Snapshot
Table 5.12. Mimetas: Key Characteristics of Organ-on-Chip Products
Table 5.13. Mimetas: Recent Developments and Future Outlook
Table 5.14. TissUse: Company Snapshot
Table 5.15. TissUse: Key Characteristics of Organ-on-Chip Products
Table 5.16. TissUse: Recent Developments and Future Outlook
Table 5.17. uFluidix: Company Snapshot
Table 5.18. uFluidix: Key Characteristics of Organ-on-Chip products
Table 5.19. uFluidix: Recent Developments and Future Outlook
Table 6.1. Patent Analysis: Most Popular CPC Symbols
Table 6.2. Patent Analysis: List of Top CPC Symbols
Table 6.3. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 6.4. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 7.1. Brand Positioning: List of Brands Positioned
Table 9.1. Organ-on-Chip: List of Partnerships and Collaborations
Table 10.1. Organ-on-Chip: List of Funding and Investments
Table 11.1. Scaffold Free Products: List of Products
Table 11.2. Scaffold Free Developers: List of Developers
Table 14.1. Cherry Biotech: Company / Organization Snapshot
Table 14.2. EDmicBio: Company / Organization Snapshot
Table 14.3. Hesperos: Company / Organization Snapshot
Table 14.4. Lena Biosciences: Company / Organization Snapshot
Table 14.5. react4life: Company / Organization Snapshot
Table 14.6. Screenin3D: Company / Organization Snaps
Table 15.1. Organ-on-Chip: Distribution by Type of Offering
Table 15.2. Organ-on-Chip: Distribution by Type of Model
Table 15.3. Organ-on-Chip: Distribution by Status of Development
Table 15.4. Organ-on-Chip: Distribution by Type of Technology / Platform
Table 15.5. Organ-on-Chip: Distribution by Number of Chips in a Plate
Table 15.6. Organ-on-Chip: Distribution by Material Used for Construction
Table 15.7. Organ-on-Chip: Distribution by Type of Polymer
Table 15.8. Organ-on-Chip: Distribution by Compatible Tissue / Organ
Table 15.9. Organ-on-Chip: Distribution by Application Area(s)
Table 15.10. Organ-on-Chip: Distribution of Developers by Year of Establishment
Table 15.11. Organ-on-Chip: Distribution of Developers by Company Size
Table 15.12. Organ-on-Chip: Distribution of Developers by Location of Headquarters
Table 15.13. Leading Developers: Distribution by Number of Organ-on-Chip Products
Table 15.14. Patent Analysis: Distribution by Type of Patents
Table 15.15. Patent Analysis: Cumulative Distribution by Publication Year
Table 15.16. Patent Analysis: Distribution by Annual Granted Patents
Table 15.17. Patent Analysis: Distribution by Annual Patent Application
Table 15.18. Patent Analysis: Distribution by Annual Granted Patents and Patent Application
Table 15.19. Patent Analysis: Distribution by Location of Headquarters
Table 15.20. Patent Analysis: Distribution by Type of Applicant
Table 15.21. Patent Analysis: Distribution by Patent Age
Table 15.22. Patent Analysis: Distribution by Geographical Region
Table 15.23. Patent Analysis: Distribution by CPC Symbols
Table 15.24. Patent Analysis: Distribution by Leading Industry Players
Table 15.25. Patent Analysis: Distribution by Leading Non-Industry Players
Table 15.26. Patent Analysis: Distribution by Leading Inventors
Table 15.27. Patent Analysis: Patent Valuation Analysis
Table 15.28. Academic Grants Analysis: Distribution by Cumulative Year-wise Trend
Table 15.29. Academic Grants Analysis: Distribution by Grant Amount Awarded
Table 15.30. Academic Grants Analysis: Distribution by Funding Institute Center
Table 15.31. Academic Grants Analysis: Distribution by Support Period
Table 15.32. Academic Grants Analysis: Distribution by Funding Institute Center and Support Period
Table 15.33. Academic Grants Analysis: Distribution by Type of Grant
Table 15.34. Academic Grants Analysis: Distribution by Purpose of Grant
Table 15.35. Academic Grants Analysis: Distribution by Activity Codes
Table 15.36. Academic Grants Analysis: Distribution by Study Section
Table 15.37. Academic Grants Analysis: Distribution by Most Popular Department
Table 15.38. Academic Grants Analysis: Distribution by Organization
Table 15.39. Academic Grants Analysis: Distribution by Support Period and Amount Awarded
Table 15.40. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Number of Grants
Table 15.41. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Amount Awarded
Table 15.42. Academic Grants Analysis: Distribution of Popular Recipient Organizations by Geographical Location
Table 15.43. Partnerships and Collaborations: Distribution by Cumulative Year-wise Trend, 2017-2022
Table 15.44. Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.45. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2017-2022
Table 15.46. Partnerships and Collaborations: Distribution by Type of Collaborator
Table 15.47. Partnerships and Collaborations: Distribution by Target Indication
Table 15.48. Partnerships and Collaborations: Distribution by Therapeutic Area
Table15.49. Partnerships and Collaborations: Distribution by Associated Organ / Tissue
Table 15.50. Most Active Players: Distribution by Number of Partnerships
Table 15.51. Partnerships and Collaborations: Distribution by Type of Agreement (Country wise)
Table 15.52. Partnerships and Collaborations: Distribution by Type of Agreement (Region wise)
Table 15.53. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.54. Funding and Investment Analysis: Distribution by Year, Type of Funding and Amount Invested (USD Million), 2017-2022
Table 15.55. Funding and Investment Analysis: Distribution by Year of Establishment and Type of Funding, 2017-2022
Table 15.56. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2017-2022
Table 15.57. Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2017-2022
Table 15.58. Funding and Investment Analysis: Distribution by Type of Funding
Table 15.59. Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 15.60. Funding and Investment Analysis: Distribution by Type of Funding and Amount Invested (USD Million)
Table 15.61. Funding and Investment Analysis: Distribution by Associated Organ / Tissue
Table 15.62. Funding and Investment Analysis: Distribution by Target Indication
Table 15.63. Funding and Investment Analysis: Distribution by Therapeutic Area
Table 15.64. Funding and Investment Analysis: Distribution by Region
Table 15.65. Most Active Players: Distribution by Number of Instances
Table 15.66. Most Active Players: Distribution by Amount Raised (USD Million)
Table 15.67. Key Investors: Distribution by Number of Funding Instances
Table 15.68. Scaffold-free 3D Cell Culture Systems: Distribution by Status of Development
Table 15.69. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product
Table 15.70. Scaffold-free 3D Cell Culture Systems: Distribution by Source of 3D Cultured Cells
Table 15.71. Scaffold-free 3D Cell Culture Systems: Distribution by Method Used for Fabrication
Table 15.72. Scaffold-free 3D Cell Culture Systems: Distribution by Material Used for Fabrication
Table 15.73. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product and Source of 3D Cultured Cells
Table 15.74. Scaffold-free 3D Cell Culture Systems: Distribution by Type of Product and Method Used for Fabrication
Table 15.75. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Year of Establishment
Table 15.76. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Company Size
Table 15.77. Scaffold-free 3D Cell Culture Systems: Distribution of Developers by Location of Headquarters
Table 15.78. Leading Developers: Analysis by Number of Scaffold Free Products
Table 15.79. Tree Map Representation: Analysis by Type of Product and Company Size
Table 15.80. Global Organ-on-Chip Market, Conservative, Base and Optimistic Forecast Scenario, 2022 - 2035 (USD Million)
Table 15.81. Organ-on-Chip Market: Distribution by Type of Product, 2022 and 2035 (USD Million)
Table 15.82. Organ-on-Chip Market for Organ(s) Based Models, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.83. Organ-on-Chip Market for Disease(s) Based Models, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.84. Organ-on-Chip Market: Distribution by Application Area, 2022 and 2035 (USD Million)
Table 15.85. Organ-on-Chip Market for Cancer Research, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.86. Organ-on-Chip Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.87. Organ-on-Chip Market for Stem Cell Research, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.88. Organ-on-Chip Market for Tissue Engineering and Regenerative Medicine, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.89. Organ-on-Chip Market: Distribution by Purpose, 2022 and 2035 (USD Million)
Table 15.90. Organ-on-Chip Market for Research Purposes, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.91. Organ-on-Chip Market for Therapy Development, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.92. Organ-on-Chip Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Million)
Table 15.93. Organ-on-Chip Market in North America, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.94. Organ-on-Chip Market in Europe, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.95. Organ-on-Chip Market in Asia-Pacific, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)
Table 15.96. Organ-on-Chip Market in Rest of the World, Conservative, Base and Optimistic Forecast Scenario, 2022-2035 (USD Million)

List Of Companies

  1. 180 Degree Capital
  2. 4Dcell
  3. abc biopply
  4. Accelera
  5. AIM Biotech
  6. Alexandria Venture Investments
  7. Altana Investissements
  8. AlveoliX
  9. AMSBIO
  10. ANRI
  11. Aracari Biosciences
  12. ARLD
  13. AstraZeneca
  14. AxoSim
  15. AXT
  16. Bpifrance
  17. Bayer
  18. Beijing Da Oak Technology
  19. Beijing Daxiang Technology
  20. Benson Capital Partners
  21. BEOnChip
  22. BGI Group
  23. Bi/ond
  24. Biosigma
  25. BIOFABICS
  26. BiomimX
  27. Barcelona Liver Bioservices (BLB)
  28. bm?t beteiligungsmanagement thüringen (bm|t)
  29. Brigham and Women's Hospital 
  30. Businesses Private Angels
  31. Cedars-Sinai Medical Center
  32. CELLnTEC
  33. CellSpring
  34. Chamber of Commerce Milan Monza Brianza Lodi
  35. Cherry Biotech
  36. CIC Place de l'Innovation
  37. CIENCE
  38. CITIC Securities
  39. CN Bio
  40. Congressionally Directed Medical Research Programs
  41. Corning Life Sciences
  42. Coulter IDEApitch
  43. Cyprotex
  44. Dalian Institute of Chemical Physics, Chinese Academy of Sciences
  45. DEFTA Partners
  46. Digital Healthcare Partners
  47. Draper 
  48. Dynamic42
  49. EDmicBio
  50. Duke University
  51. Eindhoven University of Technology
  52. EIT Health
  53. Emulate
  54. eNUVIO
  55. Essential Pharma
  56. European Union
  57. Evonik Venture Capital
  58. faCellitate
  59. Fennik Life Sciences
  60. FHNW University
  61. Fidia Farmaceutici
  62. Fluigent
  63. FORWARD.one
  64. Georgia Research Alliance
  65. Great Stuff Ventures
  66. Harvard College
  67. Harvard University
  68. HCS Pharma
  69. Hesperos
  70. HG Initiative
  71. Hoxton Ventures
  72. iiCON
  73. Imec
  74. INITIO CELL
  75. Innospark Ventures
  76. Innovate UK
  77. InSCREENeX
  78. InSphero
  79. InvivoSciences
  80. Javelin Biotech
  81. Jiksak Bioengineering
  82. Johns Hopkins University
  83. Kirkstall
  84. Leiden University Medical Center 
  85. Lena Biosciences
  86. LifeForce Capital
  87. Lonza
  88. Massachusetts Institute of Technology
  89. MBL International
  90. MediFuture
  91. Merck KGaA
  92. Merieux Equity Partners
  93. MesoBioTech
  94. MicroBrain Biotech
  95. MicroFIT
  96. Micronit
  97. MicroOrganoLab
  98. Microtissues
  99. MIMETAS
  100. Minifab
  101. Mittelständische Beteiligungsgesellschaft
  102. Morgan Noble
  103. Nanobiose
  104. National Cancer Institute
  105. National Center for Advancing Translational Sciences
  106. National Institute on Aging
  107. National Institute of Health
  108. National Institute of Neurological Disorders and Stroke
  109. National Science Foundation
  110. Néovacs
  111. NetAngels
  112. NETRI
  113. NeuroProof
  114. New York Ventures
  115. Neuro-Zone
  116. Nexcelom Bioscience
  117. National Health Research Institutes (NHRI)
  118. Nikon
  119. Nortis
  120. Ohara Pharmaceutical
  121. OLS - OMNI Life Science
  122. OMX Ventures
  123. OncoBone
  124. Partnership Fund for New York City
  125. Pear Bio
  126. Pensées
  127. Pfizer
  128. Philip Morris International
  129. PreciGenome
  130. Qureator
  131. RASA
  132. React4life
  133. REVIVO BioSystems
  134. Roche
  135. SAICO Biosystems
  136. Sanofi
  137. S-BIO
  138. ScienCell Research Laboratories
  139. Scottish EDGE
  140. ScreenIn3D
  141. SOSV
  142. Sparkasse Jena-Saale-Holzland
  143. STEMCELL Technologies
  144. Suzhou Jiyan Biomedical Technology
  145. SynVivo
  146. Tachyon Ventures
  147. Takeda
  148. TARA Biosystems
  149. The Administrators of the Tulane Educational Fund
  150. The Idea Village
  151. Thermo Fisher Scientific
  152. Thuringian Ministry of Economics, Science and Digital Society (TMWWDG) 
  153. TissUse
  154. Trancos Ventures
  155. uFluidix
  156. UNIIQ
  157. University of California
  158. University of Central Florida
  159. University of Luxembourg
  160. University of Pennsylvania
  161. University of Pittsburgh
  162. University of Washington
  163. University of Washington School of Medicine
  164. University of Washington School of Pharmacy
  165. U.S. Food and Drug Administration (USFDA)
  166. Vanderbilt University
  167. Visikol
  168. Wake Forest University Health Sciences
  169. Wavemaker Partners
  170. Wyss Institute
  171. Xona Microfluidics 
  172. Yokogawa

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com